Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ONTX Onconova Therapeutics, Inc. daily Stock Chart
ONTX [NASD]
Onconova Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-3.63 Insider Own1.80% Shs Outstand67.93M Perf Week-17.17%
Market Cap19.69M Forward P/E- EPS next Y-2.53 Insider Trans69.59% Shs Float67.93M Perf Month-19.70%
Income-21.40M PEG- EPS next Q-0.48 Inst Own4.30% Short Float1.51% Perf Quarter-86.36%
Sales2.20M P/S8.95 EPS this Y87.60% Inst Trans34.05% Short Ratio0.13 Perf Half Y-91.45%
Book/sh-0.98 P/B- EPS next Y8.30% ROA-195.30% Target Price13.77 Perf Year-90.91%
Cash/sh0.07 P/C4.10 EPS next 5Y- ROE- 52W Range0.10 - 4.83 Perf YTD-86.26%
Dividend- P/FCF- EPS past 5Y64.80% ROI-428.90% 52W High-93.99% Beta2.18
Dividend %- Quick Ratio0.70 Sales past 5Y-23.70% Gross Margin- 52W Low182.28% ATR0.07
Employees25 Current Ratio0.70 Sales Q/Q0.00% Oper. Margin- RSI (14)42.78 Volatility12.15% 36.57%
OptionableNo Debt/Eq- EPS Q/Q20.60% Profit Margin- Rel Volume1.13 Prev Close0.27
ShortableYes LT Debt/Eq- EarningsNov 26 Payout- Avg Volume7.63M Price0.29
Recom2.20 SMA206.74% SMA50-44.77% SMA200-88.04% Volume8,660,538 Change6.50%
Mar-01-18Reiterated H.C. Wainwright Buy $6 → $7.50
Jan-17-18Downgrade Maxim Group Buy → Hold
Oct-09-17Initiated H.C. Wainwright Buy $6
Apr-27-17Initiated Laidlaw Buy $10
Jul-01-15Upgrade Piper Jaffray Neutral → Overweight
May-05-15Initiated H.C. Wainwright Buy $6
Dec-10-19 03:07PM  Onconova Therapeutics, Inc. Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-Market GlobeNewswire
Dec-09-19 09:00AM  Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical Trial Design at the American Society of Hematology 2019 Annual Meeting GlobeNewswire
08:00AM  Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market GlobeNewswire
Dec-07-19 08:35AM  The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Dec-06-19 08:49AM  Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 6, 2019: TSLA, ONTX, XHB, BIG, SFIX Benzinga +19.82%
07:30AM  Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US GlobeNewswire
Nov-25-19 09:26AM  Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering GlobeNewswire -9.27%
Nov-22-19 02:46PM  Bucks County biopharm firm enters into licensing deal, embarks on stock sale American City Business Journals -5.80%
Nov-21-19 11:23AM  Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering GlobeNewswire -45.71%
10:16AM  Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada GlobeNewswire
Nov-07-19 07:30AM  Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition GlobeNewswire -9.50%
Oct-24-19 07:30AM  Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update GlobeNewswire -9.35%
Sep-24-19 10:15AM  Bucks County biopharm firm opts for private over public stock sale American City Business Journals
Sep-23-19 08:52AM  Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock GlobeNewswire -28.13%
Sep-19-19 07:39AM  The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO Benzinga -5.11%
Sep-18-19 10:05AM  Onconova Therapeutics Announces Termination of Proposed Public Offering GlobeNewswire
Sep-16-19 07:30AM  Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit GlobeNewswire -15.00%
Aug-23-19 01:23PM  Edited Transcript of ONTX earnings conference call or presentation 14-Aug-19 1:00pm GMT Thomson Reuters StreetEvents
Aug-14-19 07:30AM  Onconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results GlobeNewswire
Aug-12-19 07:30AM  Onconova Therapeutics and Mission Bio Partner to Advance Precision Oncology Clinical Trials Employing Single-Cell Genomics GlobeNewswire
Aug-07-19 07:30AM  Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2019 Financial Results GlobeNewswire
Aug-06-19 10:30AM  Onconova Therapeutics (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jun-10-19 07:30AM  Onconova Therapeutics Announces Presentations at the 24th Congress of the European Hematology Association GlobeNewswire
May-30-19 06:26PM  Edited Transcript of ONTX earnings conference call or presentation 14-May-19 1:00pm GMT Thomson Reuters StreetEvents
May-28-19 07:30AM  Onconova Therapeutics Announces Presentations at Three Upcoming Conferences GlobeNewswire
May-14-19 07:30AM  Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results GlobeNewswire
May-13-19 12:52PM  Newtown biopharm firm could reap $50M from Chinese licensing deal American City Business Journals
07:30AM  Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and Commercialize Rigosertib in Greater China GlobeNewswire
May-07-19 07:30AM  Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2019 Financial Results GlobeNewswire
May-06-19 07:30AM  Onconova Therapeutics Announces Presentations at the 15th International Symposium on Myelodysplastic Syndromes (MDS 2019) in Copenhagen, Denmark GlobeNewswire
Apr-02-19 07:30AM  Onconova Therapeutics to Present Update at the 2019 HCW Global Life Sciences Conference in London, April 7-9 GlobeNewswire +9.17%
02:36AM  Edited Transcript of ONTX earnings conference call or presentation 26-Mar-19 1:00pm GMT Thomson Reuters StreetEvents
Mar-26-19 07:30AM  Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results GlobeNewswire -10.41%
Mar-25-19 07:30AM  Onconova Achieves Over 75 Percent of Planned Enrollment in Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes GlobeNewswire
Mar-19-19 07:30AM  Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results GlobeNewswire
Mar-12-19 07:30AM  Onconova Therapeutics, Inc. to Participate at the 31st Annual ROTH Conference March 17-19, 2019 in Orange County, CA GlobeNewswire
Feb-04-19 08:00AM  Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City GlobeNewswire
Jan-31-19 07:30AM  Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City GlobeNewswire +27.05%
Jan-22-19 07:30AM  Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL GlobeNewswire
Jan-16-19 01:08PM  Bucks County biopharm firm names new CEO American City Business Journals -8.90%
Jan-15-19 05:15PM  Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer GlobeNewswire
Jan-02-19 07:30AM  Onconova Submits Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine (Vidaza®) for First-Line Myelodysplastic Syndromes (MDS) GlobeNewswire +15.17%
Dec-31-18 07:30AM  Onconova to Meet Investors and Potential Partners at China Focus and the 37th Annual J.P. Morgan Healthcare Conferences in San Francisco GlobeNewswire
Dec-10-18 07:30AM  Onconova Welcomes Avi Oler, JD, MBA, as Vice President, Corporate Development and General Counsel GlobeNewswire
Dec-03-18 07:30AM  Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting GlobeNewswire
Nov-16-18 01:47PM  Edited Transcript of ONTX earnings conference call or presentation 13-Nov-18 2:00pm GMT Thomson Reuters StreetEvents
Nov-13-18 07:00AM  Onconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018 GlobeNewswire -18.20%
Nov-07-18 08:30AM  Onconova Welcomes Richard (Ric) Woodman, M.D., as Chief Medical Officer (CMO) GlobeNewswire
Nov-06-18 10:30AM  Onconova Therapeutics (ONTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Nov-05-18 08:30AM  Onconova Announces Four Presentations from Rigosertib Clinical Trials in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting & Exposition GlobeNewswire
Nov-01-18 08:30AM  Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2018 Financial Results GlobeNewswire +8.56%
Oct-29-18 08:30AM  Onconova Therapeutics to Meet with Potential Investors and Business Development Partners at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark GlobeNewswire
Oct-17-18 08:30AM  Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib GlobeNewswire
Oct-10-18 08:30AM  Onconova Therapeutics to Present Update at the 2018 BIO Investor Forum in San Francisco GlobeNewswire
Sep-27-18 08:00AM  Today's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences ACCESSWIRE -11.77%
Sep-26-18 12:12PM  Bucks County biopharm firm implements reverse stock split American City Business Journals
Sep-25-18 09:16AM  Onconova Therapeutics Announces Reverse Stock Split GlobeNewswire
Aug-21-18 09:46AM  Edited Transcript of ONTX earnings conference call or presentation 14-Aug-18 1:00pm GMT Thomson Reuters StreetEvents +6.10%
08:30AM  Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes (MDS) to South America with Pint Pharma GlobeNewswire
Aug-14-18 08:00AM  Onconova Therapeutics Reports Business Highlights and Financial Results for Second Quarter 2018 GlobeNewswire -9.73%
07:00AM  Onconova Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Aug-07-18 08:00AM  Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2018 Financial Results GlobeNewswire
Jul-17-18 07:25AM  Free Technical Research on OPKO Health and Three More Biotech Equities ACCESSWIRE
Jun-21-18 08:00AM  Onconova Therapeutics Announces Promotion for Steven M. Fruchtman, M.D. GlobeNewswire
Jun-07-18 08:30AM  Onconova Therapeutics Announces Presentation at the 23rd Congress of the European Hematology Association GlobeNewswire +41.48%
May-29-18 08:00AM  Onconova Therapeutics, Inc. to Present at the 8th Annual LD Micro Invitational ACCESSWIRE +10.40%
May-25-18 07:21PM  Who Are The Top Investors In Onconova Therapeutics Inc (NASDAQ:ONTX)? Simply Wall St.
May-22-18 07:00AM  Free Technical Insights on OPKO Health and Three Other Biotech Stocks ACCESSWIRE
May-16-18 08:20PM  Edited Transcript of ONTX earnings conference call or presentation 15-May-18 1:00pm GMT Thomson Reuters StreetEvents
May-15-18 08:30AM  Onconova Therapeutics, Inc. Reports Business Highlights and Financial Results for First Quarter 2018 GlobeNewswire -6.64%
07:31AM  Analysts Expect Breakeven For Onconova Therapeutics Inc (NASDAQ:ONTX) Simply Wall St.
May-09-18 08:30AM  Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2018 Financial Results GlobeNewswire
May-03-18 08:00AM  Onconova Therapeutics to Present at the Disruptive Growth and Healthcare Conference on May 8th, 2018 GlobeNewswire
May-01-18 08:10PM  Onconova Therapeutics Inc (NASDAQ:ONTX): Does The Earnings Decline Make It An Underperformer? Simply Wall St.
06:33PM  Onconova Therapeutics Announces Closing of $28.75 Million Upsized Underwritten Public Offering GlobeNewswire
Apr-27-18 06:00AM  Onconova Therapeutics Announces Pricing of $25.0 Million Upsized Underwritten Public Offering GlobeNewswire -7.24%
Apr-19-18 08:30AM  Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting GlobeNewswire
Mar-26-18 08:30AM  Onconova Presents Promising Data from Phase 2 Expansion Study of Oral Rigosertib and Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease Symposium GlobeNewswire
Mar-15-18 08:00AM  Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American Association for Cancer Research Annual Meeting 2018 GlobeNewswire
Mar-09-18 12:13PM  Edited Transcript of ONTX earnings conference call or presentation 8-Mar-18 2:00pm GMT Thomson Reuters StreetEvents
Mar-08-18 08:00AM  Onconova Therapeutics Inc. to Host Earnings Call ACCESSWIRE -10.92%
Mar-06-18 08:30AM  Onconova Therapeutics to Present at the 30th Annual Roth Conference in March GlobeNewswire
Mar-05-18 08:00AM  Onconova Therapeutics Announces License Agreement with Pint Pharma to Commercialize Rigosertib for Treatment of Myelodysplastic Syndromes in Latin America GlobeNewswire
Mar-04-18 10:00AM  Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Research (AACR) Epigenetics Conference GlobeNewswire
Mar-01-18 12:00PM  Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2017 Financial Results GlobeNewswire
08:00AM  Onconova to Present Dose Optimization Studies with Rigosertib Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease Symposium GlobeNewswire
Feb-20-18 08:30AM  Onconova Announces Two Presentations at 2018 American Chemical Society National Meeting and Expo GlobeNewswire +14.02%
Feb-12-18 03:55PM  Onconova Therapeutics Announces Closing of $10 Million Underwritten Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Securities GlobeNewswire
Feb-08-18 06:00AM  Onconova Therapeutics Announces Pricing of $8.7 Million Underwritten Public Offering GlobeNewswire
Feb-02-18 08:30AM  Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Epigenetics Research Conference GlobeNewswire
Jan-17-18 07:30AM  Onconova Moving Forward with Phase 3 INSPIRE Pivotal Trial with Increased Sample Size Following Promising Interim Analysis GlobeNewswire
Jan-12-18 03:05PM  Onconova Therapeutics Is Looking to Spearhead the Next Drug Development Wave With Its Ongoing Trial GuruFocus.com
Jan-04-18 08:00AM  Onconova Therapeutics Announces Cooperative Research and Development Agreement for Rigosertib with the National Cancer Institute GlobeNewswire
Dec-28-17 08:30AM  Onconova Therapeutics to Present at Biotech Showcase in January GlobeNewswire
Dec-21-17 07:40AM  Wired News Onconova Signs License and Collaborative Development Agreement with HanX Biopharma for ON 123300 ACCESSWIRE
Dec-19-17 07:30AM  Onconova Therapeutics Announces License and Collaborative Development Agreement with HanX Biopharmaceuticals for ON 123300, a Dual Inhibitor of CDK4/6 + ARK5 GlobeNewswire
Dec-12-17 08:30AM  Onconova Presents Data on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2017 Meeting GlobeNewswire
Dec-08-17 05:53PM  Onconova Therapeutics Inc (ONTX): Are Analysts Right About The Drop In Earnings? Simply Wall St.
Nov-30-17 12:25PM  Does Onconova Therapeutics Incs (ONTX) Past Performance Indicate A Weaker Future? Simply Wall St.
Nov-20-17 08:30AM  Onconova Therapeutics to Present at the LD Micro Conference in December GlobeNewswire
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; a license and collaboration agreement with HanX Biopharmaceuticals, Inc.; and a collaboration agreement with Inceptua Medicines Access for a pre-approval access program related to intravenous rigosertib. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reddy E PremkumarDirectorNov 25Buy0.20500,000100,000544,546Nov 26 07:57 AM
MARINO JAMES JDirectorNov 25Buy0.20150,00030,000166,942Nov 26 07:53 AM
Fruchtman Steven MPresident, Chief Executive OffNov 25Buy0.20149,00029,800149,426Nov 26 07:51 AM
Guerin Mark PatrickChief Financial OfficerNov 25Buy0.2087,50017,50087,844Nov 26 07:50 AM
OLER ABRAHAM N.VP Corp Dev & Gen CounselNov 25Buy0.2075,00015,00075,000Nov 26 07:46 AM
MEHTA VIRENDirectorNov 25Buy0.20250,00050,000250,857Nov 27 08:33 AM
MARINO JAMES JDirectorSep 25Buy1.607,26011,61616,942Sep 26 06:22 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 24Sale1.1916,70019,873616,389Sep 26 04:16 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 23Sale1.2337,24245,968633,089Sep 24 04:08 PM
ARMISTICE CAPITAL, LLC10% OwnerSep 23Sale1.2710,24913,016816,702Sep 25 05:41 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 20Sale1.6275,119121,430670,331Sep 24 04:08 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 18Sale2.1049,995105,014745,450Sep 20 04:05 PM
683 Capital Management, LLCFormer 10% OwnerSep 18Sale2.03506,8771,030,684460,000Sep 20 03:21 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 11Sale2.751,2473,432795,445Sep 13 04:24 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 09Sale2.774001,106796,692Sep 11 04:16 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 06Sale2.785,01513,954797,092Sep 09 04:10 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 05Sale2.754001,100802,107Sep 09 04:10 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerJul 10Sale2.812,7427,697802,507Jul 11 04:43 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerJul 09Sale2.848,18523,204805,249Jul 11 04:43 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerJun 27Sale3.451,4585,025813,434Jul 01 04:35 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerJun 25Sale3.401,3804,689814,892Jun 27 04:21 PM
open in yahoo | open in reuters | open in google